Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

Journal of the American College of Cardiology

Volumn 46, Issue 5, 2005, Pages 761-769

  Beinart, Sean C ^a   Kolm, Paul ^a   Veledar, Emir ^a   Zhang, Zefeng ^a   Mahoney, Elizabeth M ^b   Bouin, Olivier ^c   Gabriel, Sylvie ^c   Jackson, Joseph ^d   Chen, Roland ^d   Caro, Jaime ^e   Steinhubl, Steven ^f   Topol, Eric ^g   Weintraub, William S ^a,h  

^a EMORY UNIVERSITY   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c SANOFI   (France)

^d BRISTOL MYERS SQUIBB   (United States)

^e CARO RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL OBSERVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSIS RELATED GROUP; DRUG COST; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICARE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RISK REDUCTION; STROKE; SURVIVAL; TREATMENT OUTCOME;

ASPIRIN; CEREBROVASCULAR ACCIDENT; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 24044552753     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.03.073     Document Type: Article

References (39)

1. M.E. Bertrand, V. Legrand, J. Boland Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study Circulation 98 1998 1597 1603
2. M.B. Leon, D.S. Baim, J.J. Popma Stent Anticoagulation Restenosis Study Investigators A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting N Engl J Med 339 1998 1665 1671
3. A. Schomig, F.J. Neumann, A. Kastrati A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents N Engl J Med 334 1996 1084 1089
4. P. Urban, C. Macaya, H.J. Rupprecht Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS) Circulation 98 1998 2126 2132
5. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
6. S.R. Steinhubl, P.B. Berger, J.T. Mann 3rd Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention a randomized controlled trial JAMA 288 2002 2411 2420
7. American Heart Association Heart Disease and Stroke Statistics - 2003 Update 2002 American Heart Association Dallas, TX
8. E.M. Mahoney, S.R. Mehta, Y. Yuan Long-term cost effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing PCI after presenting with acute coronary syndromes without ST-segment elevation Am Heart J 2005 In press
9. W.S. Weintraub, E.M. Mahoney, A. Lamy Long-term cost effectiveness of clopidogrel in patients with acute coronary syndromes without ST-segment elevation J Am Coll Cardiol 2005 In press
10. M. Gold, J. Siegal, L. Russel, M. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York, NY
11. M. Drummond, B. O'Brien, G.L. Stoddart, G. Torrance Methods for the economic evaluation of health care programmes 1987 Oxford University Press Oxford, United Kingdom
12. Centers for Medicare and Medicaid Services. Medicare Part A. Available at: www.cms.gov/statistics/medpar/shtstay01drg.pdf. Accessed July 11, 2005.
13. The Medstat Group DRG Guide Descriptions and Normative Values 1994 Medstat Group Ann Arbor, MI
14. J. Mitchell, R. Burge, A. Lee Per case prospective payment for episodes of hospital care 1995 U.S. Department of Commerce National Technical Information Service Springfield, VA
15. E.M. Mahoney, C.T. Jurkovitz, H. Chu Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction JAMA 288 2002 1851 1858
16. A. Peeters, A.A. Mamun, F. Willekens, L. Bonneux A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort Eur Heart J 23 2002 458 466
17. J. Caro, K.J. Ishak, K. Migliaccio-Walle Estimating survival for cost-effectiveness analysis a case study in atherothrombosis Value in Health 7 2004 627 635
18. W. Downey, P. Beck, M. McNutt, M.R. Stang, W. Osei, J. Nichol Health databases in Saskatchewan B.L. Strom Pharmacoepidemiology 3rd edition 2000 Wiley Chinchester, United Kingdom 325 345
19. A. Lamy, S. Chrolavicius, A. Gafni The cost-effectiveness of the use of clopidogrel in acute coronary syndromes based upon the CURE study (abstr) Circulation 106 2002 II758
20. F.J. Nieto, J. Coresh Adjusting survival curves for confounders a review and a new method Am J Epidemiol 143 1996 1059 1068
21. J. Lee, C. Yoshizawa, L. Wilkens, H.P. Lee Covariance adjustment of survival curves based on Cox's proportional hazards regression model Comput Appl Biosci 8 1992 23 27
22. R.W. Makuch Adjusted survival curve estimation using covariates J Chronic Dis 35 1982 437 443
23. W.A. Ghali, H. Quan, R. Brant Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models JAMA 286 2001 1494 1497
24. J. Caro, K. Migliaccio-Walle, K.J. Ishak, W.S. Weintraub Estimating life-years lost due to atherothrombotic events flexible survival functions to use in disease modeling (abstr) J Am Coll Cardiol 43 Suppl A 2004 425A
25. J. Lee, C. Yoshiwaza, L. Wilkens, H.P. Lee Covariance adjustment of survival curves based on Cox's proportional hazards regression model Comput Appl Biosci 8 1992 23 27
26. B. Efron, R. Tibshirani An Introduction to the Bootstrap 1993 Chapman and Hall New York, NY
27. W.S. Weintraub Cardiovascular Health Care Economics 2003 Humana Press Totawa, NJ
28. V.M. Fried, K. Prager, A.P. MacKay, H. Zia Chartbook on Trends in the Health of Americans 2003 National Center for Health Statistics Hyattsville, MD
29. Bauer C, Chapman D, Lin P, et al. The CEA registry: standardizing the methods and practices of cost-effectiveness analysis. Harvard Center for Risk Analysis. Available at: http://www.hsph.harvard.edu/cearegistry/. Accessed July 11, 2005.
30. B. Jonsson, M. Johannesson, J. Kjekshus Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) Eur Heart J 17 1996 1001 1007
31. J. Tsevat, K.M. Kuntz, E.J. Orav, M.C. Weinstein, F.M. Sacks, L. Goldman Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels Am Heart J 141 2001 727 734
32. H.M. Krumholz, R.C. Pasternak, M.C. Weinstein Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction N Engl J Med 327 1992 7 13
33. S.R. Mehta, S. Yusuf, R.J. Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention the PCI-CURE study Lancet 358 2001 527 533
34. P. Lindgren, B. Jonsson, S. Yusuf Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden a long-term model based on the Cure trial J Intern Med 255 2004 562 570
35. J.M. Gaspoz, P.G. Coxson, P.A. Goldman Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease N Engl J Med 346 2002 1800 1806
36. B. Jonsson Economics of drug treatment for which patients is it cost-effective to lower cholesterol? Lancet 358 2001 1251 1256
37. P.A. Cowper, K. Udayakumar, M.H. Sketch Jr., E.D. Peterson Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention J Am Coll Cardiol 45 2005 369 376
38. N.S. Kleiman, N. Lakkis, C.P. Cannon Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes J Am Coll Cardiol 40 2002 1044 1050
39. Z. Ghazzal, S. Ashfaq, D.C. Morris Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era Am Heart J 145 2003 1006 1012